POPULAR CLASS OF A DIABETIC DRUG DECREASES GLAUCOMA RISK

 In this study,  type 2 diabetic patients taking Glucagon-like Peptide-1 Receptor Agonist (GLP-1RAs) have an initial 19% reduced glaucoma risk, increasing to a 29% reduction after 3 years.   

Examples of GLP-1RAs include Exanatide (Byetta), Semaglutide (Ozempic), Liraglutide (Victoza, Saxenda), and Lixisenatide (Adlyxin).  

MYOPIA CONTROL SPECTACLES SHOW DECREASED EFFECTIVENESS IN PATIENTS WITH CONVERGENCE EXCESS

 

According to this study, "myopic subjects with convergence excess had faster elongation (resulting in faster progression of myopia) than normal myopic children in DIMS wearers (those who wore the myopic control spectacles). 

The article suggests that this occurs because convergence excess causes an accommodative lag that creates greater peripheral retinal defocus, thus counteracting the effect of the myopia control lenses.